Twist Bioscience Corporation (TWST) Reports Positive Preclinical Data for SARS-CoV-2 Antibodies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Twist Bioscience Corporation (TWST) Tops Q4 EPS by 16c, Revenues Beat
November 23, 2020 7:25 AM ESTTwist Bioscience Corporation (NASDAQ: TWST) reported Q4 EPS of ($0.54), $0.16 better than the analyst estimate of ($0.70). Revenue for the quarter came in at $32.43 million versus the consensus estimate of $22.67 million.
FISCAL 2020 FOURTH QUARTER FINANCIAL RESULTS
Orders: Total orders received for the fourth quarter of fiscal 2020 were $42.7 million, compared to $20.0 million for the same period of fiscal 2019.Revenue: Total revenues were $32.4 million for the fourth quarter of fiscal 2020 compared to $15.7 million for the same period of fiscal 2019.Cost of Revenues: Cost of revenues for the fourth quarter of fiscal 2020 was $17.6 million... More